|
TW212139B
(enExample)
*
|
1991-04-15 |
1993-09-01 |
Yamanouchi Pharma Co Ltd |
|
|
US6726930B1
(en)
*
|
1993-09-09 |
2004-04-27 |
Penwest Pharmaceuticals Co. |
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
|
US5455046A
(en)
*
|
1993-09-09 |
1995-10-03 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
|
US5773025A
(en)
*
|
1993-09-09 |
1998-06-30 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems--amorphous drugs
|
|
TW487582B
(en)
*
|
1995-08-11 |
2002-05-21 |
Nissan Chemical Ind Ltd |
Method for converting sparingly water-soluble medical substance to amorphous state
|
|
EP0893999B8
(en)
|
1996-03-18 |
2003-01-02 |
Nissan Chemical Industries, Limited |
Process for producing efonidipine hydrochloride preparations
|
|
JP3148256B2
(ja)
|
1996-07-08 |
2001-03-19 |
エドワード メンデル カンパニー.,インコーポレーテッド |
高用量難溶性薬物用持続放出マトリックス
|
|
EP0901786B1
(en)
*
|
1997-08-11 |
2007-06-13 |
Pfizer Products Inc. |
Solid pharmaceutical dispersions with enhanced bioavailability
|
|
EP1745774A3
(en)
|
1997-08-11 |
2007-04-11 |
Pfizer Products Inc. |
Solid pharmaceutical dispersions with enhanced bioavailability
|
|
US6056977A
(en)
|
1997-10-15 |
2000-05-02 |
Edward Mendell Co., Inc. |
Once-a-day controlled release sulfonylurea formulation
|
|
US6350786B1
(en)
†
|
1998-09-22 |
2002-02-26 |
Hoffmann-La Roche Inc. |
Stable complexes of poorly soluble compounds in ionic polymers
|
|
ATE400251T1
(de)
*
|
1999-02-09 |
2008-07-15 |
Pfizer Prod Inc |
Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
|
|
DE60039802D1
(de)
*
|
1999-02-10 |
2008-09-25 |
Pfizer Prod Inc |
Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
|
|
EP1027888B1
(en)
*
|
1999-02-10 |
2009-06-10 |
Pfizer Products Inc. |
Osmotic system for delivery of solid amorphous dispersions of drugs
|
|
US6706283B1
(en)
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
|
DE60039379D1
(de)
*
|
1999-02-10 |
2008-08-21 |
Pfizer Prod Inc |
Pharmazeutische feste Dispersionen
|
|
DE60038536T2
(de)
|
1999-09-30 |
2009-06-10 |
Penwest Pharmaceuticals Co. |
Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
|
|
MXPA02006079A
(es)
*
|
1999-12-20 |
2004-08-23 |
Nicholas J Kerkhof |
Proceso para producir particulas de nanometro mediante secado por aspersion de lecho fluido.
|
|
GEP20053427B
(en)
|
1999-12-23 |
2005-01-25 |
Pfizer Prod Inc |
Pharmaceutical Compositions Providing Enhanced Drug Concentrations
|
|
US7115279B2
(en)
|
2000-08-03 |
2006-10-03 |
Curatolo William J |
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
|
|
WO2002038126A2
(en)
*
|
2000-11-08 |
2002-05-16 |
Aeromatic-Fielder Ag |
A process for production of particles for pharmaceutical compositions having increased bioavailability
|
|
DE10058772A1
(de)
*
|
2000-11-27 |
2002-06-06 |
Falk Pharma Gmbh |
Verfahren zur Herstellung leicht löslicher Arzneimittelformulierungen und entsprechende Formulierungen
|
|
CA2450957A1
(en)
|
2001-06-22 |
2003-01-03 |
Pfizer Products Inc. |
Pharmaceutical compositions of dispersions of drugs and neutral polymers
|
|
US20030170309A1
(en)
*
|
2001-06-22 |
2003-09-11 |
Babcock Walter C. |
Pharmaceutical compositions containing polymer and drug assemblies
|
|
AR038375A1
(es)
*
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
|
WO2005117834A1
(en)
*
|
2004-05-27 |
2005-12-15 |
Janssen Pharmaceutica N.V. |
Solid dispersions of a basic drug compound and a polymer containing acidic groups
|
|
ATE409462T1
(de)
|
2004-05-28 |
2008-10-15 |
Pfizer Prod Inc |
Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
|
|
JPWO2006064906A1
(ja)
*
|
2004-12-17 |
2008-06-12 |
小野薬品工業株式会社 |
非晶質性組成物
|
|
US20080213383A1
(en)
*
|
2005-09-06 |
2008-09-04 |
Astellas Pharma Inc. |
Fine particles of poorly water-soluble drug having enteric material adsorbed on particle surface
|
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
|
MX2010000617A
(es)
|
2007-07-17 |
2010-05-17 |
Plexxikon Inc |
Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
|
|
US20100240711A1
(en)
|
2007-09-21 |
2010-09-23 |
Shionogi & Co., Ltd. |
Solid preparation comprising npyy5 receptor antagonist
|
|
EP2223702B1
(en)
*
|
2007-12-03 |
2019-05-08 |
Tomita Pharmaceutical Co., Ltd. |
Core particle for pharmaceutical preparation
|
|
WO2009140105A2
(en)
|
2008-05-14 |
2009-11-19 |
Merck & Co., Inc. |
Formulations for cathepsin k inhibitors
|
|
EA022924B1
(ru)
|
2009-04-03 |
2016-03-31 |
Ф.Хоффманн-Ля Рош Аг |
ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
|
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
|
WO2011031620A1
(en)
*
|
2009-09-11 |
2011-03-17 |
Transtech Pharma, Inc. |
Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
|
|
NZ629615A
(en)
|
2009-11-06 |
2016-01-29 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
BR112012031667A2
(pt)
|
2010-06-14 |
2016-11-08 |
Dow Global Technologies Llc |
composição
|
|
SI2672967T1
(sl)
|
2011-02-07 |
2018-12-31 |
Plexxikon Inc. |
Spojine in postopki za kinazno modulacijo in indikacije zanjo
|
|
AR085279A1
(es)
|
2011-02-21 |
2013-09-18 |
Plexxikon Inc |
Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
|
|
AU2012225459A1
(en)
|
2011-03-08 |
2013-10-10 |
Zalicus Pharmaceuticals Ltd. |
Solid dispersion formulations and methods of use thereof
|
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
|
EP2837391B1
(en)
|
2013-08-12 |
2017-05-10 |
Shin-Etsu Chemical Co., Ltd. |
Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
|
|
EP3089736B1
(en)
|
2013-12-31 |
2025-07-23 |
Ascendia Pharmaceuticals, LLC |
Pharmaceutical compositions for poorly water-soluble compounds
|
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
|
WO2017035408A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
|
WO2018005552A1
(en)
|
2016-06-27 |
2018-01-04 |
Achillion Pharmaceuticals, Inc. |
Quinazoline and indole compounds to treat medical disorders
|
|
CA3053818A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
|
|
WO2018175648A1
(en)
*
|
2017-03-21 |
2018-09-27 |
Bioduro, Llc |
Gastrointestinal-protective formulations for oral delivery of proteins and peptides
|
|
EP3841086B1
(en)
|
2018-08-20 |
2025-04-23 |
Achillion Pharmaceuticals, Inc. |
Pharmaceutical compounds for the treatment of complement factor d medical disorders
|
|
WO2020051532A2
(en)
|
2018-09-06 |
2020-03-12 |
Achillion Pharmaceuticals, Inc. |
Macrocyclic compounds for the treatment of medical disorders
|
|
WO2020081723A1
(en)
|
2018-10-16 |
2020-04-23 |
Georgia State University Research Foundation, Inc. |
Carbon monoxide prodrugs for the treatment of medical disorders
|
|
EP4076420A4
(en)
|
2019-12-19 |
2024-03-13 |
Georgia State University Research Foundation, Inc. |
Compounds for the treatment of bacterial infections and potentiation of antibiotics
|
|
EP4107166A4
(en)
|
2020-02-20 |
2024-06-26 |
Achillion Pharmaceuticals, Inc. |
HETEROARYL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D-MEDIATED DISORDERS
|
|
EP4216946A4
(en)
|
2020-09-23 |
2024-11-13 |
Achillion Pharmaceuticals, Inc. |
Pharmaceutical compounds for the treatment of complement mediated disorders
|